Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Authors Randi J Hagerman, Deborah A Hall, Sarah Coffey, Maureen Leehey, James Bourgeois, et al

Published 6 June 2008 Volume 2008:3(2) Pages 251—262

DOI https://dx.doi.org/10.2147/CIA.S1794

Randi J Hagerman1,2, Deborah A Hall3, Sarah Coffey1,2, Maureen Leehey3, James Bourgeois4, John Gould5, Lin Zhang6, Andreea Seritan4, Elizabeth Berry-Kravis7–9, John Olichney6, Joshua W Miller10, Amy L Fong11, Randall Carpenter12, Cathy Bodine13, Louise W Gane1,2, Edgar Rainin1, Hillary Hagerman1, Paul J Hagerman14

1M.I.N.D. Institute, 2Department of Pediatrics, 4Department of Psychiatry & Behavioral Sciences, 5Department of Urology, 6Department of Neurology, 10Department of Pathology and Laboratory Medicine, 14Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA; 3Department of Neurology, University of Colorado, Denver, CO, USA; 7Department of Pediatrics, Neurology, and Biochemistry, 8Department of Neurological Sciences, 9Department of Biochemistry, Rush University Medical Center, Chicago, IL, USA; 11Physical Edge, Inc., Davis, CA, USA; 12Seaside Therapeutics, Cambridge, MA, USA; 13Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center, Denver, CO, USA

Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.

Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Lozano R, Hare EB, Hagerman RJ

Neuropsychiatric Disease and Treatment 2014, 10:1769-1779

Published Date: 16 September 2014

Readers of this article also read:

USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study

Frankova S, Jirsa M, Merta D, Neroldova M, Urbanek P, Senkerikova R, Spicak J, Sperl J

Therapeutics and Clinical Risk Management 2015, 11:1853-1861

Published Date: 17 December 2015

Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease

Kunisawa T, Yamagishi A, Suno M, Nakade S, Honda N, Kurosawa A, Sugawara A, Tasaki Y, Iwasaki H

Therapeutics and Clinical Risk Management 2015, 11:107-114

Published Date: 17 January 2015

Prevalence of stress in junior doctors during their internship training: a cross-sectional study of three Saudi medical colleges’ hospitals

Abdulghani HM, Irshad M, Al Zunitan MA, Al Sulihem AA, Al Dehaim MA, Al Esefir WA, Al Rabiah AM, Kameshki RN, Alrowais NA, Sebiany A, Haque S

Neuropsychiatric Disease and Treatment 2014, 10:1879-1886

Published Date: 25 September 2014

Diagnosis and management of microscopic colitis: current perspectives

Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hultgren Hörnquist E, Tysk C

Clinical and Experimental Gastroenterology 2014, 7:273-284

Published Date: 21 August 2014

Genetic association between the dopamine D1-receptor gene and paranoid schizophrenia in a northern Han Chinese population

Yao J, Ding M, Xing JX, Xuan JF, Pang H, Pan YQ, Wang BJ

Neuropsychiatric Disease and Treatment 2014, 10:645-652

Published Date: 17 April 2014

Diabetes, glycemic control and risk of medical glaucoma treatment: A population-based case-control study

Lotte G Welinder, Anders H Riis, Lars L Knudsen, et al

Clinical Epidemiology 2009, 1:125-131

Published Date: 21 October 2009

Association of the BANK1 R61H variant with systemic lupus erythematosus in Americans of European and African ancestry

Struan FA Grant, Michelle Petri, Jonathan P Bradfield, Cecilia E Kim, Erin Santa, et al

The Application of Clinical Genetics 2009, 2:1-5

Published Date: 9 December 2008